Mild Liver Enzyme Elevation on Eliquis: Monitoring Recommended, Not a Contraindication
Your ALT of 84 U/L and AST of 61 U/L represent mild elevations (<3 times upper limit of normal) that do not require stopping Eliquis, but warrant investigation of the underlying cause and monitoring.
Understanding Your Liver Enzyme Levels
Your transaminase levels fall into the "mild" elevation category 1. Using contemporary reference ranges:
- ALT 84 U/L is approximately 2.5-3.5 times the upper limit (normal: 19-33 U/L depending on sex) 2, 3
- AST 61 U/L is approximately 2 times the upper limit (normal: 26-32 U/L depending on sex) 2, 4
The ALT/AST ratio of 1.4 suggests a hepatocellular pattern of injury rather than cholestatic disease 1.
Eliquis and Liver Safety
Apixaban (Eliquis) has an excellent hepatic safety profile and is not known to cause clinically significant liver injury 5, 6. The FDA label specifically notes that patients should inform their doctor if they have liver problems before starting Eliquis 6, but mild transaminase elevations are not a contraindication to use.
Key evidence:
- Unlike ximelagatran (a withdrawn anticoagulant that caused severe hepatotoxicity), dabigatran studies showed no disproportionate increase in liver enzymes 5
- Apixaban clinical trials in orthopedic surgery showed transaminase increases occurred in <1% of patients, with similar rates to enoxaparin 6
- No hepatotoxicity signal has been identified with apixaban in large-scale studies 5, 6
Most Likely Causes of Your Elevation
The most common causes of mild transaminase elevation in this range are 1:
- Nonalcoholic fatty liver disease (NAFLD) - prevalence 20-30% in general population, up to 70% with obesity
- Alcohol-related liver disease - typically shows AST/ALT ratio >2 (yours is <1, making this less likely)
- Medications other than Eliquis - particularly statins, NSAIDs, or other hepatotoxic drugs
- Metabolic syndrome components - diabetes, obesity, insulin resistance
What You Should Do
Immediate Actions:
- Continue Eliquis - do not stop without consulting your prescribing physician, as this increases stroke risk 6
- Review all medications and supplements with your doctor for potential hepatotoxins
- Assess for metabolic risk factors (BMI >23.5-25.8 kg/m² is the critical threshold for ALT elevation) 2
Diagnostic Workup:
Obtain abdominal ultrasound as first-line imaging to evaluate for 1:
- Hepatic steatosis (fatty liver)
- Structural liver abnormalities
- Biliary obstruction (though less likely given your pattern)
Additional laboratory testing should include:
- Hepatitis B and C serologies
- Fasting glucose and lipid panel
- Consider iron studies, autoimmune markers if initial workup unrevealing
Follow-up Timeline:
- Repeat liver enzymes in 4-6 weeks to assess trajectory
- If enzymes continue rising or exceed 5 times upper limit, more urgent evaluation needed
- If stable or improving, continue monitoring every 3-6 months
Critical Pitfalls to Avoid
Do not discontinue Eliquis without medical guidance - the stroke risk from stopping anticoagulation far exceeds the risk from mild transaminase elevation 6
Do not assume Eliquis is the cause - the evidence strongly suggests other etiologies are far more likely 5, 1
Do not delay workup - while mild elevations are common, identifying reversible causes (alcohol, medications, metabolic factors) can prevent progression to cirrhosis 1
Watch for warning signs requiring urgent evaluation:
- Jaundice (yellowing of skin/eyes)
- Right upper quadrant pain
- Dark urine or pale stools
- Unexplained bleeding or bruising beyond what's expected with anticoagulation
The Bottom Line
Your liver enzyme pattern suggests a mild hepatocellular process unrelated to Eliquis. The most likely culprits are fatty liver disease or other medications. Continue your anticoagulation, pursue standard evaluation for elevated transaminases with ultrasound and metabolic workup, and monitor enzyme trends 1, 6.